Since the immunotherapy with DB (i.p., five consecutive days, 3 mg/kg bw/day, start of treatment: four days after tumor cell implantation) showed, in our syngeneic tumor model, strong antitumor efficacy against NB, resulting in constant tumor regression [12,14], we aimed to establish a more resistant version of this tumor model allowing the evaluation of the combinatorial immunotherapy with DB and FAP-IL-2v. The gene discussed is FAP; the disease is neuroblastoma.